Alefacept

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Moderate to Severe Chronic Plaque Psoriasis

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Trial Timeline

Jul 1, 2004 → Mar 1, 2005

NCT ID

NCT00168753

About Alefacept

Alefacept is a approved stage product being developed by Astellas Pharma for Moderate to Severe Chronic Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00168753. Target conditions include Moderate to Severe Chronic Plaque Psoriasis.

What happened to similar drugs?

17 of 20 similar drugs in Moderate to Severe Chronic Plaque Psoriasis were approved

Approved (17) Terminated (4) Active (3)

✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved

✅tacrolimusAstellas PharmaApproved

✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

✅Risankizumab + DeucravacitinibAbbVieApproved

✅adalimumabAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅AdalimumabAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01267643	Phase 1	Terminated	May 1, 2011	Apr 16, 2013	Aplastic Anemia
NCT01226420	Phase 2	Terminated	Oct 1, 2010	Aug 1, 2012	Chronic Graft-versus-host Disease
NCT00808223	Phase 2	Completed	Apr 1, 2009	Feb 1, 2012	Psoriasis
NCT00815633	Approved	Terminated	Dec 1, 2008	Mar 1, 2010	Pityriasis Rubra Pilaris
NCT00953329	Approved	Terminated	Feb 1, 2008	Dec 1, 2008	Chronic Plaque Psoriasis
NCT00832585	Approved	Completed	Jan 1, 2008	Oct 1, 2009	Atopic Dermatitis
NCT00658606	Approved	Completed	Oct 1, 2007	Dec 1, 2009	Plaque Psoriasis
NCT00168753	Approved	Completed	Jul 1, 2004	Mar 1, 2005	Moderate to Severe Chronic Plaque Psoriasis
NCT00674063	Phase 3	Completed	Jul 1, 2003	Apr 1, 2004	Chronic Plaque Psoriasis
NCT00692172	Phase 3	Completed	Dec 1, 2001	Nov 1, 2004	Psoriasis

Competing Products

20 competing products in Moderate to Severe Chronic Plaque Psoriasis

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	44
CT-P13 SC Auto-Injector + Placebo Auto-Injector	Celltrion	Phase 3	44
CT-P17 + EU-approved Humira	Celltrion	Phase 3	40
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	47
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	44
Afimkibart + Placebo	Chugai Pharmaceutical	Phase 3	47
Pexidartinib	Daiichi Sankyo	Phase 1	29
CS-3150	Daiichi Sankyo	Phase 3	40
tacrolimus	Astellas Pharma	Approved	43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)	Sun Pharmaceutical	Phase 2	35
Tildrakizumab 100 mg + Placebo	Sun Pharmaceutical	Phase 3	44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo	Sun Pharmaceutical	Phase 2/3	42
Ranirestat + Placebo	Eisai	Phase 2/3	38
E6007 + Placebo	Eisai	Phase 2	35
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
KHK4827-Active + KHK4827-Placebo	Kyowa Kirin	Approved	35
KHK4827 + Placebo	Kyowa Kirin	Phase 2	35
Stelara + Bmab1200	Biocon	Phase 3	40
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe	Biocon	Phase 3	40